Trial Profile

A Phase 2, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of AT-02

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AT-02 (Primary)
Indications Amyloidosis
Focus Adverse reactions
Sponsors Attralus

Most Recent Events

30 May 2024 According to Attralus media release, trial design presented at the XIX International Symposium on Amyloidosis (ISA)
19 Oct 2023 Status changed from not yet recruiting to recruiting.
14 Aug 2023 The protocol was amended increase in study Time Frame Up to 112 weeks from 56 weeks.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com